BREAKING NEWS
Results from the Women’s Health Initiative released today show that combined hormone therapy is linked to a modest increase in breast cancer deaths. Read the story.
NEWS
Cancer Screening Continues Even after Patients Are Diagnosed with Terminal Cancer
A number of patients with advanced, incurable cancer continue to undergo routine cancer screening tests that are unlikely to provide any medical benefit, reported researchers led by Dr. Camelia Sima from Memorial Sloan-Kettering Cancer Center in the October 13 issue of the Journal of the American Medical Association (JAMA). Read more > >
Abiraterone Improves Survival in Metastatic Prostate Cancer
Preliminary study results prompted unblinding of trial, drug offered to control armSimilar Early-phase Trials Prohibit Different Drugs, Undermining Outcomes
Variability could make it harder to compare study outcomes and compromise patient safetySurgical Procedure Reduces Disability and Pain Caused by Spine Fractures in Cancer Patients
Study shows balloon kyphoplasty is superior to nonsurgical management
COMMENTARY
Guest Commentary: Bringing Science to the Market
To many people, NCI is thought of principally as a source of funding for cancer research. But the Institute is also an important driver of small business and technology development. Through its Small Business Innovation Research (SBIR) program, NCI plays a critical role in helping small businesses develop and commercialize innovative technologies that can improve how we prevent, diagnose, and treat cancer. Read more > >
IN DEPTH
Hormone Therapy Linked to Modest Increase in Breast Cancer Deaths
WHI study ties hormone use to increased incidence of invasive breast cancer
Testing a “Smarter” Biopsy for Prostate Cancer
An image-guided biopsy may detect cancer missed by conventional methods
Partners in Crime: Using Synthetic Lethality to Identify New Cancer Targets
Some components of cancer cell signaling networks work together to keep the cell alive
Featured Clinical Trial: Eliminating Hairy Cell Leukemia Minimal Residual Disease
When is the better time to give rituximab with standard cladribine?
UPDATES
FDA Update
- Regulatory Science Initiative Will Prepare FDA for New Technologies
- Warning about Carboplatin Dosing for Physicians and Principal Investigators
HHS Update
- Advisory Committee Will Work to Heighten Breast Cancer Awareness
Notes
- NCI’s Ira Pastan and Carl Wu Elected to Institute of Medicine
- Meet NCI Experts at APHA
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
